Publications

  1. Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol 2017 May 01; 19 (5):625-635
    View PubMed
  2. Chamberlain M, Junck L, Brandsma D, Soffietti R, Ruda R, Raizer J, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Walker J, van den Bent M, Wen PY, Jaeckle KA. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol 2017 Apr 01; 19 (4):484-492
    View PubMed
  3. Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, Penas-Prado M, Robins HI, Belanger K, Schultz C, Hunter G, Mehta M. Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro Oncol 2017 Feb 01; 19 (2):252-258
    View PubMed
  4. Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG 2nd, Deming R, Burri SH, Menard C, Chung C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA 2016 Jul 26; 316 (4):401-9
    View PubMed
  5. Berg AK, Buckner JC, Galanis E, Jaeckle KA, Ames MM, Reid JM. Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure. J Clin Pharmacol 2015 Nov; 55 (11):1303-12 Epub 2015 June 26
    View PubMed
  6. Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Flynn PJ, Ligon KL, Buckner JC, Sarkaria JN. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol 2015 Sep; 17 (9):1261-9 Epub 2014 Dec 18
    View PubMed
  7. Chamberlain M, Soffietti R, Raizer J, Ruda R, Brandsma D, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Junck L, van den Bent M, Wen PY, Jaeckle KA. Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol 2014 Sep; 16 (9):1176-85 Epub 2014 May 27
    View PubMed
  8. Jaeckle KA. Oligodendroglial tumors. Semin Oncol. 2014 Aug; 41(4):468-77. Epub 2014 Jun 30.
    View PubMed
  9. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014 Feb 20; 370 (8):699-708
    View PubMed
  10. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013 Nov 10; 31 (32):4085-91 Epub 2013 Oct 07
    View PubMed
  11. Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 2013 Sep 01; 19 (17):4816-23 Epub 2013 July 05
    View PubMed
  12. Dignam J, Won M, Blumenthal DT, Vogelbaum MA, Aldape KD, Colman H, Chakravarti A, Jeraj R, Armstrong TS, Wefel JS, Brown PD, Jaeckle KA, Schiff D, Atkins JN, Brachman D, Werner-Wasik M, Komaki R, Sulman EP, Mehta MP. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 2013 Jun 20; 31 (18_suppl):1
    View PubMed
  13. Won M, Blumenthal DT, Vogelbaum MA, Colman H, Jenkins RB, Chakravarti A, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Dignam J, Atkins JN, Brachman D, Werner-Wasik M, Komaki R, Gilbert MR, Mehta MP, Aldape KD. Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). J Clin Oncol 2013 Jun 20; 31 (18_suppl):LBA2010
    View PubMed
  14. Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, Schwerkoske J, Mazurczak M, Gross H, Pajon E, Jaeckle K, Galanis E. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol. 2012 Feb; 14(2):215-21. Epub 2011 Nov 16.
    View PubMed
  15. Jiang L, Li Z, Finn LE, Personnet DA, Edenfield B, Foran JM, Jaeckle KA, Reimer R, Menke DM, Ketterling RP, Tun HW. Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma. Int J Clin Exp Pathol. 2012; 5(1):72-6. Epub 2012 Jan 01.
    View PubMed
  16. Sarkaria JN, Galanis E, Wu W, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Buckner JC. North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011 Oct 01; 81 (2):468-75 Epub 2010 Sept 23
    View PubMed
  17. Jaeckle KA, Decker PA, Ballman KV, Flynn PJ, Giannini C, Scheithauer BW, Jenkins RB, Buckner JC. Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. J Neurooncol. 2011 Aug; 104(1):253-9. Epub 2010 Dec 12.
    View PubMed
  18. Jaeckle KA. Metastases involving spinal cord, roots, and plexus. Continuum. 2011 Aug; 17(4):855-71.
  19. Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, Schaefer PL, Dakhill SR, Jaeckle KA. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys. 2011 Jun 1; 80(2):347-53. Epub 2010 May 25.
    View PubMed
  20. van den, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011 Jun; 12(6):583-93. Epub 2011 Apr 05.
    View PubMed
  21. Sarkaria JN, Peller PJ, Galanis E, Jacobson MS, Wu W, Jaeckle KA, Buckner JC. FLT-PET analysis of early response to everolimus in newly diagnosed glioblastoma patients enrolled on NCCTG N057K. J Clin Oncol 2011 May 20; 29 (15_suppl):e12501
    View PubMed
  22. Jaeckle KA, Schiff D, Anderson SK, Galanis E, Stella PJ, Flynn PJ, Sarkaria JN, Scheithauer BW, Erickson BJ, Buckner JC, NCCTG. NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study. J Clin Oncol 2011 May 20; 29 (15_suppl):2033
    View PubMed
  23. Anderson SK, Lafky JM, Carrero XW, Kimlinger TK, Halling TM, Kumar S, Flynn PJ, Gross HM, Jaeckle KA, Buckner JC, Galanis E. Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in patients (pts) with recurrent glioblastoma (rGBM) treated with bevacizumab (BEV) and sorafenib (SOR). J Clin Oncol 2011 May 20; 29 (15_suppl):2019
    View PubMed
  24. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi M, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge SC, Brown PD, Chakravarti A, Curran WJ, Mehta MP. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol 2011 May 20; 29 (15_suppl):2006
    View PubMed
  25. Sarkaria JN, Galanis E, Wu W, Dietz AB, Kaufmann TJ, Gustafson MP, Brown PD, Uhm JH, Rao RD, Doyle L, Giannini C, Jaeckle KA, Buckner JC. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res 2010 Nov 15; 16 (22):5573-80 Epub 2010 Oct 04
    View PubMed
  26. Jaeckle KA, Ballman KV, Giannini C, Schomberg PJ, Ames MM, Reid JM, McGovern RM, Safgren SL, Galanis E, Uhm JH, Brown PD, Hammack JE, Arusell R, Nikcevich DA, Morton RF, Wender DB, Buckner JC. Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM. J Neurooncol 2010 Aug; 99 (1):73-80 Epub 2010 Jan 09
    View PubMed
  27. Jaeckle KA. Neurologic manifestations of neoplastic and radiation-induced plexopathies. Semin Neurol. 2010 Jul; 30(3):254-62. Epub 2010 Jun 24.
    View PubMed
  28. Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O'Fallon JR, Jaeckle KA, Prados MD. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro Oncol 2010 Feb; 12 (2):164-72 Epub 2009 Dec 21
    View PubMed
  29. Jaeckle KA, Ballman K, Furth A, Buckner JC. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 2009 Oct 13; 73 (15):1207-13
    View PubMed
  30. Sarkaria JN, Galanis E, Wu W, Giannini C, Jaeckle KA, Doyle L, Uhm J, Brown P, Dietz AB, Buckner J. NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients. J Clin Oncol 2009 May 20; 27 (15_suppl):2019
    View PubMed
  31. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009 Apr 20; 27 (12):2052-8 Epub 2009 Mar 23
    View PubMed
  32. Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, Felten SJ, Nikcevich DA, Wiesenfeld M, Jaeckle KA, Galanis E, North Central Cancer Treatment Group. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neurooncol 2009 Apr; 92 (2):165-75 Epub 2008 Dec 10
    View PubMed
  33. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM Jr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C, Buckner JC, North Central Cancer Treatment Group Study N0177. Phase III trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 2008 Dec 01; 26 (34):5603-9 Epub 2008 Oct 27
    View PubMed
  34. Grothey A, Adjei AA, Alberts SR, Perez EA, Jaeckle KA, Loprinzi CL, Sargent DJ, Sloan JA, Buckner JC, North Central. North Central Cancer Treatment Group--achievements and perspectives. Semin Oncol. 2008 Oct; 35(5):530-44.
    View PubMed
  35. Jaeckle KA, Wu W, Kosel M, Flynn PJ, Buckner JC. Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials. J Clin Oncol 2008 May 20; 26 (15_suppl):2024
    View PubMed
  36. Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P, Edenfield B, Zubair AC, O'Neill BP, Lai WR, Park PJ, McKinney M. Pathway analysis of primary central nervous system lymphoma. Blood 2008 Mar 15; 111 (6):3200-10 Epub 2008 Jan 09
    View PubMed
  37. Blitshteyn S, Crook JE, Jaeckle KA. Is there an association between meningioma and hormone replacement therapy? J Clin Oncol. 2008 Jan 10; 26(2):279-82.
    View PubMed
  38. Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007 Jan; 9(1):29-38. Epub 2006 Nov 15
    View PubMed
  39. Blitshteyn S, Jaeckle K. Status epilepticus in patients with CNS metastases. Arch Neurol. 2007; 64(6):916.
  40. Brown PD, Jensen AW, Felten SJ, Ballman KV, Schaefer PL, Jaeckle KA, Cerhan JH, Buckner JC. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol. 2006 Dec 1; 24(34):5427-33.
    View PubMed
  41. Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol. 2006 Oct; 80(1):83-90. Epub 2006 Apr 25.
    View PubMed
  42. Krishnan S, Brown PD, Ballman KV, Fiveash JB, Uhm JH, Giannini C, Jaeckle KA, Geoffroy FJ, Nabors LB, Buckner JC, North Central Cancer Treatment Group. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1192-9. Epub 2006 Apr 19.
    View PubMed
  43. Jaeckle KA, Decker PA, Ballman KV, Flynn PJ, Giannini C, Scheithauer BW, Jenkins RB, Buckner JC. Analysis of paired glioma tissues from initial diagnosis and recurrence in patients enrolled on NCCTG clinical trials: De-differentiation and association with survival. J Clin Oncol 2006 Jun 20; 24 (18_suppl):1521
    View PubMed
  44. Buckner JC, Ballman K, Schaefer P, Furth AF, Giannini C, Scheithauer BW, Galanis E, Jaeckle KA. NCCTG 96-94-53: Clinical variables associated with overall survival (OS), progression-free survival (PFS), 6 month progression-free survival (PFS6), immediate progression (ImmProg), and response in patients enrolled in recurrent glioma clinical trials. J Clin Oncol 2006 Jun 20; 24 (18_suppl):1520
    View PubMed
  45. Ballman KV, Jaeckle KA, Schomberg P, Giannini C, Galanis E, Brown P, Arusell R, Reid J, Hammack J, Buckner J. Phase II trial of irinotecan (CPT-11) and radiation followed by irinotecan and BCNU in glioblastoma patients (pts). J Clin Oncol 2006 Jun 20; 24 (18_suppl):1562
    View PubMed
  46. Decker PA, Ballman KV, Locke DE, Brown PD, Jaeckle KA, Buckner JC, Rummans TA, Clark MM, Sloan JA. Validation of single item Linear Analogue Scale Assessments (LASAs) for assessing quality of life (QOL) in patients with newly diagnosed high-grade gliomas. J Clin Oncol 2006 Jun 20; 24 (18_suppl):8583
    View PubMed
  47. Jaeckle KA. Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment. Semin Oncol. 2006 Jun; 33(3):312-23.
    View PubMed
  48. Marshall NE, Ballman KV, Michalak JC, Schomberg PJ, Burton GV, Sandler HM, Cascino TL, Jaeckle KA, Buckner JC. Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. J Neurooncol. 2006 May; 77(3):315-20.
    View PubMed
  49. Deen HG, Miller DA, Kostick DA, Jaeckle KA. Removal of an orbital metallic foreign body to facilitate magnetic resonance imaging: technical case report. Neurosurgery 2006 May; 58 (5):E999; discussion E999
    View PubMed
  50. Deen HG, Miller DA, Kostick DA, Jaeckle KA. Removal of An Orbital Metallic Foreign Body to Facilitate Magnetic Resonance Imaging: Technical Case Report. Neurosurgery 2006 May 01; 58 (5):E999
    View PubMed
  51. Blitshteyn S, Jaeckle KA. Nonconvulsive status epilepticus in metastatic CNS disease. Neurology. 2006 Apr 25; 66(8):1261-3.
    View PubMed
  52. Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol. 2006 Mar 10; 24(8):1246-52.
    View PubMed
  53. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J. A phase 2 trial of irinotecan (CPT11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study Neurooncology. 2006; 8(2):189-193.
  54. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ, North Central Cancer Treatment Group. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005 Aug 10; 23 (23):5294-304 Epub 2005 July 05
    View PubMed
  55. Buckner JC, Ballman KV, Scheithauer BW, Arusell RM, Blair HE, Passe SM, Brown PD, Jaeckle KA, Shaw EG, Jenkins RB. NCCTG 94-72-53: Diagnostic and prognostic significance of 1p and 19q deletions in patients (pts) with low-grade oligodendroglioma and astrocytoma. J Clin Oncol 2005 Jun; 23 (16_suppl):1502
    View PubMed
  56. Ballman KV, Jaeckle KA, Brown PD, Flynn PJ, Buckner JC. NCCTG N047D: Relationship between phase II endpoints of 12 month overall survival and 6 month progression-free survival for glioblastoma multiforme (GBM) phase II trials. J Clin Oncol 2005 Jun; 23 (16_suppl):1508
    View PubMed
  57. Jaeckle KA, Ballman KV, Schomberg P, Uhm J, Schiethauer B, Giannini C, Felton S, Brown P, Jan BC, NCCTG. N997D: Pilot trial of CPT11 during RT followed by CPT11 and BCNU in newly diagnosed glioblastoma (GBM) patients: A North Central Cancer Group (NCCTG) study. J Clin Oncol 2005 Jun; 23 (16_suppl):1514
    View PubMed
  58. Blaney SM, Balis FM, Berg S, Arndt CAS, Heideman R, Geyer JR, Packer R, Adamson PC, Jaeckle K, Klenke R, Aikin A, Murphy R, McCully C, Poplack DG. Intrathecal mafosfamide: A preclinical pharmacology and phase I trial. J Clin Oncol. 2005 Mar 1; 23(7):1555-63.
    View PubMed
  59. Jaeckle KA. Neurological manifestations of neoplastic and radiation-induced plexopathies. Semin Neurol. 2004 Dec; 24(4):385-93.
    View PubMed
  60. Uhm JH, Ballman KV, Giannini C, Krauss JC, Buckner JC, James D, Scheithauer BW, O'Fallon JR, Jaeckle KA. Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma. J Clin Oncol 2004 Jul 15; 22 (14_suppl):1505
    View PubMed
  61. Jaeckle KA, Ballman K, Uhm J, O'Fallon J, Schomberg P, Scheithauer B, Giannini C, Flynn PJ, Buckner J. Comparison of survival endpoints in glioblastoma patients receiving or not receiving enzyme-inducing anticonvulsants in NCCTG Trials. J Clin Oncol 2004 Jul 15; 22 (14_suppl):1525
    View PubMed
  62. Chang SM, Prados MD, Yung WKA, Fine H, Junck L, Greenberg H, Robins HI, Mehta M, Fink KL, Jaeckle KA, Kuhn J, Hess K, Schold C. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma - A North American Brain Tumor Consortium Trial. Cancer. 2004 Apr 15; 100(8):1712-6.
    View PubMed
  63. Prados MD, Yung WKA, Fine HA, Greenberg HS, Junck L, Chang SM, Nicholas MK, Robins HI, Mehta MP, Fink KL, Jaeckle KA, Kuhn J, Hess KR, Schold SC. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro-oncol. 2004 Jan; 6(1):33-7.
    View PubMed
  64. Prados MD, Yung WKA, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro-oncol. 2004 Jan; 6(1):44-54.
    View PubMed
  65. Jaeckle KA, Hess KR, Yung WKA, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: A North American Brain Tumor Consortium study. J Clin Oncol. 2003 Jun 15; 21(12):2305-11.
    View PubMed
  66. Pudivalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Townsend JJ, Davis R, Sawaya R, Kyritsis AP. Anaplastic oligodendrogliomas: Prognostic factors for tumor recurrence and survival Oncology. 2003; 65(3):259-66.
  67. Blaney SM, Heideman R, Berg S, Adamson P, Gillespie A, Geyer JR, Packer R, Matthay K, Jaeckle K, Cole D, Kuttesch N, Poplack DG, Balis FM. Phase 1 clinical trial of intrathecal topotecan in patients with neoplastic meningitis J Clin Oncol. 2003; 21(1):243-7.
  68. Prados MD, Schold SC, Fine HA, Jaeckle K, Hochberg F, Mechtler L, Fetell MR, Phuphanich S, Feun L, Janus TJ, Forde K, Graney W. A randomized, double blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma Neurooncology. 2003; 5(2):96-103.
  69. Sherman AM, Jaeckle K, Meyers CA. Pretreatment cognitive performance predicts survival in patients with leptomeningeal disease. Cancer. 2002 Sep 15; 95(6):1311-6.
    View PubMed
  70. Jaeckle KA, Batchelor T, O'Day SJ, Phuphanich S, New P, Lesser G, Cohn A, Gilbert M, Aiken R, Heros D, Rogers L, Wong E, Fulton D, Gutheil JC, Baidas S, Kennedy JM, Mason W, Moots P, Russell C, Swinnen LJ, Howell SB. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol. 2002 May; 57(3):231-9.
    View PubMed
  71. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002 Mar 1; 20(5):1383-8.
    View PubMed
  72. Taylor SA, Rankin C, Townsend JJ, Craig JB, Vance RB, Solank DL, Brown TD, Jaeckle K. Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study. Invest New Drugs. 2002 Feb; 20(1):113-5.
    View PubMed
  73. Kunschner LJ, Fine H, Hess K, Jaeckle K, Kyritsis AP, Yung WKA. CI-980 for the treatment of recurrent or progressive malignant gliomas: National Central Nervous System Consortium Phase I-II Evaluation of CI-980. Cancer Invest. 2002; 20(7-8):948-54.
    View PubMed
  74. Taylor SA, Giroux DJ, Townsend JJ, Craig JB, Vance RB, Solanki DL, Brown TD, Jaeckle KA. Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group Study. Investig New Drugs. 2002; 20(1):113-15.
  75. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O'Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer. 2001 Jan; 84(2):157-63.
    View PubMed
  76. Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA, Prados MD, Bruner JM, Chang SM, Kyritsis AP, Gleason MJ, Hess KR. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res. 2000 Oct; 6(10):3878-84.
    View PubMed
  77. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000 Feb; 18(4):708-15.
    View PubMed
  78. Verschraegen CF, Jaeckle K, Giovanella B, Knight V, Gilbert BE. Alternative administration of camptothecin analogues. Ann N Y Acad Sci. 2000; 922:237-46.
    View PubMed
  79. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999 Nov; 5(11):3394-402.
    View PubMed
  80. Hess KR, Wong ET, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD, Yung WK. Response and progression in recurrent malignant glioma. Neuro-oncol. 1999 Oct; 1(4):282-8.
    View PubMed
  81. Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, Phuphanich S, Rogers LR, Gutheil JC, Batchelor T, Lyter D, Chamberlain M, Maria BL, Schiffer C, Bashir R, Thomas D, Cowens W, Howell SB. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999 Oct; 17(10):3110-6.
    View PubMed
  82. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999 Aug; 17(8):2572.
    View PubMed
  83. Groves MD, Maor MH, Meyers C, Kyritsis AP, Jaeckle KA, Yung WK, Sawaya RE, Hess K, Bruner JM, Peterson P, Levin VA. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1999 Aug 1; 45(1):127-35.
    View PubMed
  84. Sodeyama N, Ishida K, Jaeckle KA, Zhang L, Azuma A, Yamada M, Mizusawa H, Wada Y. Pattern of epitopic reactivity of the anti-Hu antibody on HuD with and without paraneoplastic syndrome. Journal of Neurology, Neurosurgery & Psychiatry. 1999 Jan; 66(1):97-9.
    View PubMed
  85. Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M, Yarosh DB, Bearman SI, Giroux DJ, Schold SC. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 1998 Oct; 16(10):3310-5.
    View PubMed
  86. Wong ET, Jackson EF, Hess KR, Schomer DF, Hazle JD, Kyritsis AP, Jaeckle KA, Yung WK, Levin VA, Leeds NE. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology. 1998 Mar; 50(3):777-81.
    View PubMed
  87. Taylor SA, Giroux DJ, Jaeckle KA, Panella TJ, Dakhil SR, Schold SC. Phase II study of Didemnin B in central nervous system tumors: a Southwest Oncology Group study. Invest New Drugs. 1998-1999; 16(4):331-2.
    View PubMed
  88. Przepiorka D, Jaeckle KA, Birdwell RR, Fuller GN, Kumar AJ, Huh YO, McCutcheon I. Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant. 1997 Dec; 20(11):983-7.
    View PubMed
  89. Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, Freedman RS, Kaplan AL, Kieback DG, Meyers CA, Jaeckle KA, Loyer E, Steger M, Mante R, Mavligit G, Killian A, Tang RA, Gutterman JU, Kavanagh JJ. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res. 1997 Sep; 3(9):1501-5.
    View PubMed
  90. Eng DY, DeMonte F, Ginsberg L, Fuller GN, Jaeckle K. Craniospinal dissemination of central neurocytoma. Report of two cases. J Neurosurg. 1997 Mar; 86(3):547-52.
    View PubMed
  91. Kaba SE, Kyritsis AP, Hess K, Yung WK, Mercier R, Dakhil S, Jaeckle KA, Levin VA. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol. 1997 Mar; 15(3):1063-70.
    View PubMed
  92. Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, Yung WK. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997 Feb; 40(2):271-5.
    View PubMed
  93. Vriesendorp HM, Quadri SM, Jaeckle KA, Freedman RS, Cromeens DM. Proposal for translational analysis and development of clinical radiolabeled immunoglobulin therapy. Radiotherapy & Oncology. 1996 Nov; 41(2):151-61.
    View PubMed
  94. Kyritsis AP, Yung WK, Jaeckle KA, Bruner J, Gleason MJ, Ictech SE, Flowers A, Levin VA. Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. Neurosurgery. 1996 Nov; 39(5):921-6.
    View PubMed
  95. Jaeckle KA. Paraneoplastic nervous system syndromes. Curr Opin Oncol. 1996 May; 8(3):204-8.
    View PubMed
  96. Belanich M, Pastor M, Randall T, Guerra D, Kibitel J, Alas L, Li B, Citron M, Wasserman P, White A, Eyre H, Jaeckle K, Schulman S, Rector D, Prados M, Coons S, Shapiro W, Yarosh D. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 1996 Feb 15; 56(4):783-8.
    View PubMed
  97. Moll JW, Antoine JC, Brashear HR, Delattre J, Drlicek M, Dropcho EJ, Giometto B, Graus F, Greenlee J, Honnorat J, Jaeckle KA, et al. Guidelines on the detection of paraneoplastic anti-neuronal-specific antibodies: report from the Workshop to the Fourth Meeting of the International Society of Neuro-Immunology on paraneoplastic neurological disease, held October 22-23, 1994, in Rotterdam, The Netherlands. Neurology. 1995 Oct; 45(10):1937-41.
    View PubMed
  98. Jaeckle KA. Autoimmune mechanisms in the pathogenesis of paraneoplastic nervous system disease. Clinical Neurology & Neurosurgery. 1995 Feb; 97(1):82-8.
    View PubMed
  99. Greenlee JE, Burns JB, Rose JW, Jaeckle KA, Clawson S. Uptake of systemically administered human anticerebellar antibody by rat Purkinje cells following blood-brain barrier disruption. Acta Neuropathol (Berl) 1995; 89(4):341-5.
    View PubMed
  100. Jaeckle KA. Immunotherapy of malignant gliomas. Semin Oncol. 1994 Apr; 21(2):249-59.
    View PubMed
  101. Harris CP, Sigman JD, Jaeckle KA. Intravascular malignant lymphomatosis: amelioration of neurological symptoms with plasmapheresis. Ann Neurol. 1994 Mar; 35(3):357-9.
    View PubMed
  102. Aiken RD, Jaeckle KA. Introduction: Malignant Astrocytomas. Seminars in Oncology. 1994; 21(2):125.
  103. Salcman M, Scholtz H, Kaplan RS, Kulik S, Wilson CB, Black PM, Jaeckle KA, Hepson JW Hochberg FH. Long-term survival in patients with malignant astrocytoma. Neurosurgery. 1994; 34(2):213-20.
  104. Jaeckle KA. Causes and management of headaches in cancer patients. Oncology (Huntington) 1993 Apr; 7(4):27-31; discussion 31-2, 34.
    View PubMed
  105. Sakai K, Ogasawara T, Hirose G, Jaeckle KA, Greenlee JE. Analysis of autoantibody binding to 52-kd paraneoplastic cerebellar degeneration-associated antigen expressed in recombinant proteins. Ann Neurol. 1993 Apr; 33(4):373-80.
    View PubMed
  106. Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993 Jan; 15(1):75-7.
    View PubMed
  107. Greenlee JE, Parks TN, Jaeckle KA. Type Iia (anti-Hu') antineuronal antibodies produce destruction of rat cerebellar granule neurons in vitro. Neurology. 1993; 43:2049-54.
    View PubMed
  108. Greenlee JE, Brashear HR, Jaeckle KA, Geleris A, Jordan K. Pursuing an occult carcinoma in a patient with subacute cerebellar degeneration and anticerebellar antibodies. Need for vigorous follow-up. West J Med. 1992 Feb; 156(2):199-202.
    View PubMed
  109. Blumenfeld AM, Recht LD, Chad DA, DeGirolami U, Griffin T, Jaeckle KA. Coexistence of Lambert-Eaton myasthenic syndrome and subacute cerebellar degeneration: differential effects of treatment. Neurology. 1991 Oct; 41(10):1682-5.
    View PubMed
  110. Taylor SA, Crowley J, Pollock TW, Eyre HJ, Jaeckle C, Hynes HE, Stephens RL. Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial. J Clin Oncol. 1991 Aug; 9(8):1476-9.
    View PubMed
  111. Taylor SA, Crowley J, Vogel FS, Townsend JJ, Eyre HJ, Jaeckle KA, Hynes HE, Guy JT. Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trial. Invest New Drugs. 1991 May; 9(2):195-7.
    View PubMed
  112. Jaeckle KA. Neuroimaging for central nervous system tumors. Semin Oncol. 1991 Apr; 18(2):150-7.
    View PubMed
  113. Luque FA, Furneaux HM, Ferziger R, Rosenblum MK, Wray SH, Schold SC Jr, Glantz MJ, Jaeckle KA, Biran H, Lesser M, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991 Mar; 29(3):241-51.
    View PubMed
  114. Lachance DH, O'Neill BP, Macdonald DR, Jaeckle KA, Witzig TE, Li CY, Posner JB. Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology. 1991 Jan; 41(1):95-100.
    View PubMed
  115. Jaeckle KA. Opinion on paraneoplastic syndromes. Primary Care & Cancer. 1991; 11:53-4.
  116. Jaeckle KA. Nerve plexus metastases. Neurologic Complications of System Cancer Neurologic Clinics. 1991; 9(4):857-66.
  117. Jaeckle KA, Digre KB, Jones CR, Bailey PL, McMahill PC. Central neurogenic hyperventilation: pharmacologic intervention with morphine sulfate and correlative analysis of respiratory, sleep, and ocular motor dysfunction. Neurology. 1990 Nov; 40(11):1715-20.
    View PubMed
  118. Jaeckle KA, Mittelman A, Hill FH. Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma. J Clin Oncol. 1990 Aug; 8(8):1408-18.
    View PubMed
  119. Brashear HR, Greenlee JE, Jaeckle KA, Rose JW. Anticerebellar antibodies in neurologically normal patients with ovarian neoplasms. Neurology. 1989 Dec; 39(12):1605-9.
    View PubMed
  120. Jaeckle KA, Graus F, Houghton A, Cardon-Cardo C, Nielsen SL, Posner JB. Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann Neurol. 1985 Nov; 18(5):592-600.
    View PubMed
  121. Jaeckle KA. Assessment of tumor markers in cerebrospinal fluid. Clin Lab Med. 1985 Jun; 5(2):303-15.
    View PubMed
  122. Jaeckle KA, Young DF, Foley KM. The natural history of lumbosacral plexopathy in cancer. Neurology. 1985 Jan; 35(1):8-15.
    View PubMed
  123. Jaeckle KA, Krol G, Posner JB. Evolution of computed tomographic abnormalities in leptomeningeal metastases. Ann Neurol. 1985 Jan; 17(1):85-9.
    View PubMed
  124. Sowers JJ, Jaeckle KA, Allen JH, Correa-Paz F. Computed tomography in the diagnosis of congenital cytomegalic inclusion disease. South Med J. 1982 Nov; 75(11):1421-4.
    View PubMed
  125. Jaeckle KA. Cerebrospinal fluid cytomorphology in systemic lupus erythematosus with Anton's syndrome. Acta Cytol. 1982 Jul-Aug; 26(4):532-6.
    View PubMed
  126. Jaeckle KA, Freemon FR. Pokeweed poisoning. South Med J. 1981 May; 74(5):639-40.
    View PubMed
  127. Jaeckle KA, Allen JH. Subdural hygroma: diagnosis with computed tomography. J Comput Tomogr. 1979 Sep; 3(3):201-6.
    View PubMed